Longeveron® to Present at the 37th Annual Roth Conference
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the 37th Annual Roth Conference scheduled for March 17-18, 2025. The company, which focuses on developing cellular therapies for life-threatening and chronic aging-related conditions, will conduct a fireside chat during the event.
The presentation will be accessible through the 'Events and Presentations' section of Longeveron's website, with the webcast replay remaining available for 90 days after the conference.
Longeveron (NASDAQ: LGVN), una società biotecnologica in fase clinica specializzata in medicina rigenerativa, ha annunciato la sua partecipazione al 37° Annual Roth Conference in programma per il 17-18 marzo 2025. L'azienda, che si concentra sullo sviluppo di terapie cellulari per condizioni legate all'invecchiamento cronico e minacciose per la vita, condurrà una chiacchierata informale durante l'evento.
La presentazione sarà accessibile attraverso la sezione 'Eventi e Presentazioni' del sito web di Longeveron, con la registrazione del webcast disponibile per 90 giorni dopo la conferenza.
Longeveron (NASDAQ: LGVN), una empresa de biotecnología en etapa clínica especializada en medicina regenerativa, ha anunciado su participación en la 37ª Conferencia Anual Roth programada para el 17 y 18 de marzo de 2025. La compañía, que se centra en el desarrollo de terapias celulares para condiciones relacionadas con el envejecimiento crónico y que amenazan la vida, llevará a cabo una charla informal durante el evento.
La presentación estará disponible a través de la sección 'Eventos y Presentaciones' en el sitio web de Longeveron, con la repetición de la transmisión web accesible durante 90 días después de la conferencia.
롱제버론 (NASDAQ: LGVN), 임상 단계의 재생 의학 생명공학 회사가 2025년 3월 17일부터 18일까지 예정된 제37회 로스 연례 회의에 참여한다고 발표했습니다. 생명 위협적이며 만성 노화 관련 질환에 대한 세포 치료 개발에 중점을 두고 있는 이 회사는 행사 중에 대화형 발표를 진행할 예정입니다.
발표는 롱제버론 웹사이트의 '이벤트 및 발표' 섹션을 통해 접근할 수 있으며, 회의 후 90일 동안 웹캐스트 재생이 제공됩니다.
Longeveron (NASDAQ: LGVN), une entreprise de biotechnologie en phase clinique spécialisée dans la médecine régénérative, a annoncé sa participation à la 37ème Conférence Annuelle Roth prévue pour les 17 et 18 mars 2025. L'entreprise, qui se concentre sur le développement de thérapies cellulaires pour des conditions menaçant la vie et liées au vieillissement chronique, animera une discussion informelle lors de l'événement.
La présentation sera accessible via la section 'Événements et Présentations' du site web de Longeveron, avec la rediffusion du webinaire disponible pendant 90 jours après la conférence.
Longeveron (NASDAQ: LGVN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf regenerative Medizin spezialisiert hat, hat seine Teilnahme an der 37. jährlichen Roth-Konferenz angekündigt, die für den 17. und 18. März 2025 geplant ist. Das Unternehmen, das sich auf die Entwicklung von Zelltherapien für lebensbedrohliche und chronische altersbedingte Erkrankungen konzentriert, wird während der Veranstaltung ein informelles Gespräch führen.
Die Präsentation wird über den Bereich 'Veranstaltungen und Präsentationen' auf der Website von Longeveron zugänglich sein, und die Aufzeichnung des Webcasts wird 90 Tage nach der Konferenz verfügbar bleiben.
- None.
- None.
MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025.
Details for the Company’s fireside chat:
| Date: | Tuesday, March 18, 2025 | |
| Time: | 9:00 – 9:25 a.m. PT |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B™ development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When is Longeveron (LGVN) presenting at the 37th Annual Roth Conference?
How long will the LGVN Roth Conference presentation replay be available?
Where can investors access Longeveron's (LGVN) Roth Conference presentation?
What type of therapies is Longeveron (LGVN) developing?
